Evocutis and Bradford University Collaborate on pigmented LabSkin

Published: 4-Mar-2013
Regulatory Skin Care Sun Care

Aim to discover improved ways of investigating common pigment-related skin conditions


UK-based Evocutis and the University of Bradford’s Centre for Skin Sciences are to collaborate on research that could improve the treatment of pigment-related skin conditions and the development of sun protection products.

The co-funded project will investigate adding melanocytes, the cells that produce melanin and give skin and hair its colour, to Evocutis’ LabSkin living skin equivalent model.

The project could see Wetherby, West Yorkshire-based Evocutis bring to market LabSkin models for different skin types and colours, allowing them to be used more widely in laboratories for research and development of medical and personal care products.

Bradford’s skin experts are interested in how LabSkin, a living skin equivalent, could be developed and used for research to tackle conditions such as Vitiligo (loss of pigment), Melasma (increased skin pigmentation) and common ‘age spots’.

A commercial use of pigmented LabSkin would be to test and support the marketing claims of sun protection products.

Professor Des Tobin, Director of the Centre for Skin Sciences at The University of Bradford, said: ‘We’re hopeful that this research will help us find improved ways of investigating common pigment-related skin conditions which is an area of particular interest to us, as well as helping Evocutis to develop its LabSkin model to more fully approximate human skin.’

  • Companies:
  • Evocutis
See more

You may also like

Skin Care

Venn Life Sciences acquires trading assets of Evocutis

Read more
Including intellectual property rights to Labskin and anti-acne compound SYN1113

Trending Articles

  1. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  3. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services
  5. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Skin Care

Venn Life Sciences acquires trading assets of Evocutis

Including intellectual property rights to Labskin and anti-acne compound SYN1113
Regulatory

Evocutis secures first contracts for LabSkin living skin equivalent

Offers an alternative to ethically sensitive and expensive animal and human volunteer testing
Research & Development

Evocutis joins European platform to promote alternatives to animal testing

After making presentation about its LabSkin technology
Manufacturing

Syntopix plans to buy Leeds Skin

Key attraction of acquisition is Leeds Skin’s LabSkin technology
Ingredients

Syntopix to develop new microemulsions

Wins support from Intelligent Formulation
Regulatory

Accelerating and enhancing toxicology assessments

Infographic guides users through ToxHQ’s speedy assessment features
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Subscribe now